High-level production of animal-free recombinant transferrin from Saccharomyces cerevisiae
© Finnis et al; licensee BioMed Central Ltd. 2010
Received: 15 July 2010
Accepted: 17 November 2010
Published: 17 November 2010
Animal-free recombinant proteins provide a safe and effective alternative to tissue or serum-derived products for both therapeutic and biomanufacturing applications. While recombinant insulin and albumin already exist to replace their human counterparts in cell culture media, until recently there has been no equivalent for serum transferrin.
The first microbial system for the high-level secretion of a recombinant transferrin (rTf) has been developed from Saccharomyces cerevisiae strains originally engineered for the commercial production of recombinant human albumin (Novozymes' Recombumin® USP-NF) and albumin fusion proteins (Novozymes' albufuse®). A full-length non-N-linked glycosylated rTf was secreted at levels around ten-fold higher than from commonly used laboratory strains. Modification of the yeast 2 μm-based expression vector to allow overexpression of the ER chaperone, protein disulphide isomerase, further increased the secretion of rTf approximately twelve-fold in high cell density fermentation. The rTf produced was functionally equivalent to plasma-derived transferrin.
A Saccharomyces cerevisiae expression system has enabled the cGMP manufacture of an animal-free rTf for industrial cell culture application without the risk of prion and viral contamination, and provides a high-quality platform for the development of transferrin-based therapeutics.
Transferrin (Tf) is the major iron binding protein in human plasma, responsible for the regulated delivery of iron to cells. It is a monomeric glycoprotein (~80 kDa) with the capacity to bind two ferric ions very tightly, but reversibly. Transferrin consists of two globular lobes (the N-lobe and C-lobe) each made up of two sub-domains separated by a deep cleft, which contains the binding site for a ferric ion and a synergistic carbonate anion. In the vast majority of cell types iron is acquired by the binding of iron-laden holo-transferrin to a specific transferrin receptor (TfR), followed by endocytosis of the Fe3+/Tf/TfR complex. Iron is released in the acidic conditions of the endosome, after which the Tf/TfR complex is returned to the cell surface, from where the iron-free apo-transferrin is released back into circulation .
A current major use for plasma-derived transferrin is in the preparation of media for the culture of mammalian cells. The use of such media for the production of pharmaceutical products requires stringent attention to the source materials to control the risk of viral and prion disease transmission. A recombinant microbial source avoiding the use of mammalian-derived materials provides an obvious advantage.
Therapeutic applications have also been proposed for transferrin [2, 3]. Treatment of the rare disease hereditary atransferrinemia is the most obvious, where the beneficial effects of transferrin infusion have been described . Recently, exogenous transferrin has been used to ameliorate disease in β-thalassemic mice, where improved erythropoiesis and red blood cell survival were observed after treatment with transferrin . This suggests that transferrin therapy might provide a viable alternative to blood transfusion and chelation therapy for treating human β-thalassemia and other diseases with concurrent anemia and iron overload. Furthermore, transferrin has been proposed as a means of reducing free-iron concentrations and consequent oxidative damage and infection risk [6–8]. Since transferrin is relatively resistant to proteolytic degradation and the TfR is abundant on gastrointestinal epithelial cells, transferrin fusions and conjugates with GCSF, insulin and human growth hormone have been studied for oral delivery of therapeutic proteins [9, 10]. The 7-10 day plasma half-life of fully glycosylated transferrin in humans and the 14-15 day half-life reported for carbohydrate-deficient transferrin also promise improved plasma half-life over the unfused proteins in vivo[11, 12]. Finally, overexpression of the TfR by many cancer cells has promoted interest in the use of transferrin for tumor imaging and targeted drug delivery .
Glycosylated and non-glycosylated recombinant human transferrins have been secreted from baby hamster kidney (BHK) cells. Both were shown to be fully equivalent to the serum protein in iron binding and interaction with cellular transferrin receptors, with glycosylation being unimportant for transferrin function in vitro. However, expression from mammalian cells does not meet the requirement for an inexpensive source of recombinant transferrin, and may itself rely upon an animal-derived source of transferrin in the culture media. Expression of full-length transferrin from microbial sources has previously only been reported at low levels ranging from 3-40 mg/L [14–16], although transferrin production by recombinant plants has recently been described at higher levels [17, 18]. While this could satisfy the need for an animal-free transferrin source, MALDI MS analysis of the rice-derived transferrin showed two peaks, with the mass of the predominant peak appearing 1,392 Da higher than the predicted mass, suggesting post-translational modification.
Here we describe a highly productive yeast expression system using baker's yeast, Saccharomyces cerevisiae. Successive rounds of chemical mutagenesis and selection, combined with deletion of specific endogenous genes, have produced yeast strains with improved product yield and quality [19–22]. These host strains were combined with an episomal expression vector based upon the highly stable yeast 2 μm plasmid . The expression vector contains the LEU2 selectable marker and a recombinant protein expression cassette, comprising the PRB1 promoter, a secretory leader, the coding sequence of interest and the ADH1 terminator. S. cerevisiae transformed with such vectors contains only yeast DNA and the coding sequence of interest. The yeast expression system was initially developed for the high-level secretion of recombinant human serum albumin (rHA), but studies have shown that this system can equally be used to express a diverse range of heterologous proteins. We have used this system as the basis for the development of a recombinant transferrin production platform.
Results and discussion
Removal of N-linked glycosylation sites in rTf reduces product heterogeneity and allows visualization by SDS-PAGE
PDI1 overexpression increases rTf production approximately ten-fold
rTf production titers in high cell density fed-batch fermentations
Number of fermentations
Growth rate (h-1)
Transferrin titer (g/L in supernatant)*
Novel sites were thus identified that did not have such deleterious effects. The XcmI restriction site, downstream of REP2 in the inverted repeat region (Figure 2), was one of several sites in the inverted repeat regions that did not appear to destabilize the plasmid under selective conditions (data not shown). We constructed pDB2711 by inserting a copy of PDI1 at this XcmI site with transcription in the same direction as REP2, in a plasmid otherwise the same as pDB2536 (Figure 2). DYB7 [pDB2711] gave a large increase in rTf expression in shake flasks (Figure 1, Lane C6). A similar effect was also seen in an alternative laboratory strain, JRY188, showing that this effect is not strain-specific (Figure 1, Lane C3). Fermentation titers of rTf produced from strains with single, double and multicopy PDI1 demonstrated that the increased productivity observed in SFC was also seen under production conditions, resulting in rTf titers of around 1.5 g/L (Table 1).
Functional characterization demonstrates equivalence of rTf and plasma-derived Tf
Leader sequence optimization results in rTf product with the correct N-terminus
For the commercial production of rTf the invertase leader sequence was used in combination with alternative N-linked glycosylation mutants (S415A, T613A as opposed to N413Q, N611Q) and codon optimization of the coding sequence. Fermentation of the resultant strain, DYB7 [pDB3237], under optimized conditions gave an average rTf titer of 2.29 g/L (Table 1).
Strain selection and PDI1 overexpression increased rTf expression over fifty-fold in shake flask culture
MS profiling of rTf mutants confirms reduced glycosylation compared to plasma-derived transferrin
Dissociation constants (Kd) for transferrin receptor-mediated iron-55 uptake and unspecific uptake (Bmax) by K562 cells grown in vitro with recombinant and plasma-derived transferrins
Bmax (fmol/106 cells)
Human plasma Tf (Calbiochem)
105 ± 16
2668 ± 91
104 ± 23
2543 ± 122
The high expression level (> 2 g/L) achieved in high cell density fed-batch fermentation has enabled an economically viable process to be developed for production of a high quality transferrin analogue for cell culture purposes (Novozymes' CellPrime™ rTransferrin AF). The yeast-based fermentation process utilizes a chemically defined medium consisting of only salts, trace elements, sucrose, vitamins and ammonia. This fermentation process is much less costly than equivalent mammalian cell processes and, given the much higher yeast growth rate, is also more productive in relation to capacity utilization. In addition, the cGMP process avoids the use of animal-derived materials, thereby eliminating the risk of viral and prion contamination. Use of this rTf product in mammalian cell culture instead of animal-derived transferrin allows a simple elimination of these risks while continuing to deliver iron to cells via the natural mechanism of receptor-mediated endocytosis .
The system described here allows the production of transferrin or transferrin-related products for therapeutic use [1–5, 7, 9, 11]. Proposed products include whole transferrin, adducts or conjugates (e.g. to diphtheria toxin for tumor therapy), and protein fusions. Other members of the protein family such as lactoferrin could be produced using similar approaches as well as derivatives such as mutant transferrins or truncated proteins. Transferrin fusions are of particular interest for two reasons: Firstly, the Tf/TfR interaction may provide an effective route for drug delivery to tumor cell targets; and, secondly, fusion to transferrin may allow the development of oral formulations for recombinant proteins. Thus we anticipate that the system described above will provide an enabling technology for a range of pharmaceutical products.
Plasmid and yeast strain construction
The human transferrin cDNA was excised from pcG13-Tf (kindly supplied by Robert W Evans) as a 2.37-kb Pst I DNA fragment and cloned into the unique Pst I site of pBST+  to create pDB2449. The 5'-end of the transferrin cDNA was altered to replace the native transferrin secretory leader sequence with a modified version of the pre-pro HSA/MFα1 fusion leader sequence  consisting of the amino acid sequence MKWVFIVSILFLFSSAYSRSLDKR (referred to subsequently as the "mHSA/MFα1-leader"). Additionally, the 3'-end of the transferrin cDNA was modified to introduce two TAA translation stop codons. The transferrin sequence was then cloned between the PRB1 promoter and the ADH1 terminator in the plasmid pDB2923. The expression cassette from pDB2923 was subcloned as a Not I fragment into the yeast episomal expression vector pSAC35, in this case to produce pDB2506. To facilitate the expression of non-N-linked glycosylated transferrin, the asparagine residues at positions 413 and 611 were replaced with glutamine residues (CAA codon) by PCR mutagenesis to create the transferrin (N413Q, N611Q) expression cassette in pDB2536.
For genomic integration of PDI1, a Pst I-Sca I DNA fragment containing the S. cerevisiae PDI1 gene  was blunt ended and cloned into Sma I linearized pUC19 to create plasmid pAYE561. A 2.94-kb Kpn I DNA fragment from pAYE561 (containing the PDI1 gene) was inserted into YIplac211 at the Kpn I site to create pDB2389. Plasmid pDB2389 was linearized with Bsu 36I for integration into the PDI1 locus of DYB7, creating the strain DP9.
In order to insert the PDI1 gene onto the expression plasmid, a linker containing a Sma I site was inserted into pSAC35  at the Xcm I site downstream of the REP2 gene to create plasmid pDB2688. A 1.9-kb S. cerevisiae PDI1 fragment containing 212-bp upstream of the start codon and 148-bp downstream of the termination codon was then cloned, in the same orientation as REP2, into the Sma I site to create plasmid pDB2690. The expression cassette used to produce pDB2536 was cloned, using Not I sites, into pDB2690 to create pDB2711.
Leader sequence modifications resulting in the "mHSA-leader", lacking the final RSLDKR hexapeptide of the "mHSA/MFα1-leader" or the yeast invertase leader MLLQAFLFLLAGFAAKISA, were made to produce pDB2929 and pDB3557 respectively. Further sequence modifications to the transferrin sequence, including codon optimization of the open reading frame and reversed orientation of the Not I expression cassette, resulted in production of pDB3237. pDB3768 contains an S32A mutation in the transferrin coding sequence to control O-glycosylation. To investigate the effect of PDI1 overexpression, the Not I expression cassette from pDB3237 was cloned into pSAC35, resulting in production of pDB3235 (Not I cassette in same orientation as LEU2) and pDB3236 (Not I cassette in opposite orientation to LEU2). Not I cassette orientation had no effect on rTf production levels.
Yeast strains used in this work
cir0 MATa, leu2-3, leu2-112, ura3-52, trp1, his4, sir3, rme, GAL
cir0 MAT a, leu2-3, leu2-112
rHA-overproducing strain derived from DB1 by chemical mutagenesis. Known genotype: cir0 MAT a, leu2-3, leu2-112
rHA-overproducing strain derived from DS569 by chemical mutagenesis. Known genotype: cir0 MAT a, leu2-3, leu2-112 ubc4 ura3 yap3::URA3 lys2 hsp150::LYS2
DYB7 with PDI1, URA3 and YIplac211 integrated at the PDI1 locus
Description of plasmids used in development of the rTf expression system
2 μm-derived yeast episomal expression vector
pSAC35 with mHSA/MFα1-leader-rTf cassette at Not I site
pSAC35 with mHSA/MFα1-leader-rTf (N413Q, N611Q) cassette at Not I site
pSAC35 with PDI1 inserted at Xcm I site after REP2
pDB2690 with mHSA/MFα1-leader-rTf (N413Q, N611Q) cassette at Not I site
pDB2690 with mHSA-leader-rTf (N413Q, N611Q) at Not I site
pDB2690 with invertase-leader-rTf (N413Q, N611Q) at Not I site
pDB2690 with invertase-leader-rTf (S415A, T613A) at Not I site
pDB2690 with invertase-leader-rTf (S32A, S415A, T613A) at Not I site
pSAC35 with invertase-leader-rTf (S415A, T613A) at Not I site
pSAC35 with invertase-leader-rTf (S415A, T613A) at Not I site
Shake flask cultures with 10 ml BMMD (buffered minimal medium dextrose  in 50 ml conical flasks) were grown for five days at 30°C, 200 rpm. Shake flasks were inoculated to OD600 = 0.1 with two-day starter cultures of transformants grown in 10 ml BMMD in 50 ml conical flasks. Fed-batch fermentations were carried out in a 10 L Braun Biostat C fermenter at 30°C .
A two-step ion-exchange chromatography procedure was used to prepare rTf for protein characterization. An SP-Sepharose Fast Flow column was used as the first step, followed by a DEAE-Sepharose Fast Flow column as the second (GE Healthcare).
Urea gel electrophoresis
Urea gel electrophoresis was performed using a modification of the procedure of Makey and Seal  with commercial minigels (6% homogeneous TBE Urea, Invitrogen). Apo-transferrin was prepared by dialysis against 0.1 M citrate, 0.1 M acetate, 10 mM EDTA pH 4.5. Reconstituted holo-transferrin was prepared from this solution by addition of 10 μl 1 mM FeNTA (prepared freshly as an equimolar solution of ferric chloride in disodium nitrilotriacetic acid) to a 50 μl aliquot and allowed to stand for 10 minutes to permit CO2 dissolution for completion of iron binding before electrophoretic analysis.
55Fe uptake competition in erythroleukemic K562 cells
For iron-55 uptake from labeled diferric transferrin, K562 erythroleukemic cells cultured in RPMI cell culture medium under standard conditions (bicarbonate-buffered, 5% CO2, antibiotics, 10% fetal calf serum) were washed with serum-free medium containing HEPES-buffer and 1 mg/ml of bovine serum albumin and used at a concentration of 10 million cells/ml in this medium. The samples tested were prepared as equimolar concentrations of apo-transferrin. Transferrin was loaded with iron according to a standard procedure using ferric nitrilotriacetate as the iron source . Increasing concentrations of plasma-derived transferrin or the respective rTf sample (0, 25, 100, 200, 400, 800, 1600 nM), labeled with 55Fe, were mixed with 100 μl of medium. The reaction was started by the addition of 100 μl of cell suspension. A second series of parallel experiments was carried out in the presence of a hundred-fold excess of unlabeled diferric transferrin to account for unspecific binding. Since the counting data showed that iron uptake was linear during the first 30 minutes, the reaction was always stopped after 25 minutes at 37°C by immersion in an ice-bath. Three 60 μl aliquots of cell suspension were transferred to new tubes, and the cells were centrifuged in the cold and again after addition of an oil layer of diethylphthalate/dibutylphthalate. The supernatant was removed, and the cell pellet transferred into a counter vial and lysed with 0.5 M KOH + 1% Triton X-100. The lysates were neutralized with 1 M HCl after overnight lysis, mixed with Readysafe scintillation cocktail, and counted in the Packard Liquid Scintillation Counter. The results are presented as fmol 55Fe/million cells.
N-terminal amino acid sequence analysis was carried out by automated Edman degradation using an Applied Biosystems 494 Procise® Protein Sequencer. Mass spectrometry samples were introduced into a hybrid quadrupole time-of-flight mass spectrometer (QqOaTOF, Applied Biosystems, QSTAR-XL®), equipped with an electrospray (IonSpray™) ion source in positive ion mode, using flow injection analysis (FIA), and, typically, 1 minute of spectral scans were averaged.
We acknowledge the valuable contributions made by Katherine Jones, Jason Cameron, Lee Blackwell, Karl Nicholls, Ashley Taylor, Anne Cox, Joanne Waters, Marc Williamson and Tony Greenfield from Novozymes Biopharma UK Limited.
- Li H, Qian ZM: Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002, 22 (3): 225-250. 10.1002/med.10008.View ArticleGoogle Scholar
- Gomme PT, McCann KB, Bertolini J: Transferrin: structure, function and potential therapeutic actions. Drug Discov Today. 2005, 10 (4): 267-273. 10.1016/S1359-6446(04)03333-1.View ArticleGoogle Scholar
- Weinberg ED: Therapeutic potential of human transferrin and lactoferrin. ASM News. 2002, 68 (2): 65-69.Google Scholar
- Hayashi A, Wada Y, Suzuki T, Shimizu A: Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. Am J Hum Genet. 1993, 53 (1): 201-213.Google Scholar
- Li H, Rybicki AC, Suzuka SM, von Bonsdorff L, Breuer W, Hall CB, Cabantchik ZI, Bouhassira EE, Fabry ME, Ginzburg YZ: Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010, 16 (2): 177-182. 10.1038/nm.2073.View ArticleGoogle Scholar
- Sahlstedt L, von Bonsdorff L, Ebeling F, Ruutu T, Parkkinen J: Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients. Br J Haematol. 2002, 119 (2): 547-553. 10.1046/j.1365-2141.2002.03836.x.View ArticleGoogle Scholar
- von Bonsdorff L, Tolo H, Lindeberg E, Nyman T, Harju A, Parkkinen J: Development of a pharmaceutical apotransferrin product for iron binding therapy. Biologicals. 2001, 29 (1): 27-37. 10.1006/biol.2001.0273.View ArticleGoogle Scholar
- de Vries B, Walter SJ, von Bonsdorff L, Wolfs TG, van Heurn LW, Parkkinen J, Buurman WA: Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation. 2004, 77 (5): 669-675. 10.1097/01.TP.0000115002.28575.E7.View ArticleGoogle Scholar
- Bai Y, Ann DK, Shen WC: Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci USA. 2005, 102 (20): 7292-7296. 10.1073/pnas.0500062102.View ArticleGoogle Scholar
- Amet N, Wang W, Shen WC: Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release. 2010, 141 (2): 177-182. 10.1016/j.jconrel.2009.09.007.View ArticleGoogle Scholar
- Schmidt SR: Fusion-proteins as biopharmaceuticals - applications and challenges. Curr Opin Drug Discov Devel. 2009, 12 (2): 284-295.Google Scholar
- Arndt T: Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem. 2001, 47 (1): 13-27.Google Scholar
- Mason AB, Miller MK, Funk WD, Banfield DK, Savage KJ, Oliver RW, Green BN, MacGillivray RT, Woodworth RC: Expression of glycosylated and nonglycosylated human transferrin in mammalian cells. Characterization of the recombinant proteins with comparison to three commercially available transferrins. Biochemistry. 1993, 32 (20): 5472-5479. 10.1021/bi00071a025.View ArticleGoogle Scholar
- MacGillivray RTA, Mason AB: Transferrins. Molecular and Cellular Iron Transport. Edited by: Templeton DM. 2002, 41-69. Marcel Dekker, IncGoogle Scholar
- Mizutani K, Hashimoto K, Takahashi N, Hirose M, Aibara S, Mikami B: Structural and functional characterization of recombinant human serum transferrin secreted from Pichia pastoris. Biosci Biotechnol Biochem. 2010, 74 (2): 309-315. 10.1271/bbb.90635.View ArticleGoogle Scholar
- Mukaiyama H, Tohda H, Takegawa K: Overexpression of protein disulfide isomerases enhances secretion of recombinant human transferrin in Schizosaccharomyces pombe. Appl Microbiol Biotechnol. 2010, 86 (4): 1135-1143. 10.1007/s00253-009-2393-x.View ArticleGoogle Scholar
- Brandsma ME, Diao H, Wang X, Kohalmi SE, Jevnikar AM, Ma S: Plant-derived recombinant human serum transferrin demonstrates multiple functions. Plant Biotechnol J. 2010, 8 (4): 489-505. 10.1111/j.1467-7652.2010.00499.x.View ArticleGoogle Scholar
- Zhang D, Nandi S, Bryan P, Pettit S, Nguyen D, Santos MA, Huang N: Expression, purification, and characterization of recombinant human transferrin from rice (Oryza sativa L.). Protein Expr Purif. 2010, 74 (1): 69-79. 10.1016/j.pep.2010.04.019.View ArticleGoogle Scholar
- Sleep D, Belfield GP, Ballance DJ, Steven J, Jones S, Evans LR, Moir PD, Goodey AR: Saccharomyces cerevisiae strains that overexpress heterologous proteins. Biotechnology (N Y). 1991, 9 (2): 183-187. 10.1038/nbt0291-183.View ArticleGoogle Scholar
- Sleep D, Finnis C, Turner A, Evans L: Yeast 2 micron plasmid copy number is elevated by a mutation in the nuclear gene UBC4. Yeast. 2001, 18 (5): 403-421. 10.1002/yea.679.View ArticleGoogle Scholar
- Kerry-Williams SM, Gilbert SC, Evans LR, Ballance DJ: Disruption of the Saccharomyces cerevisiae YAP3 gene reduces the proteolytic degradation of secreted recombinant human albumin. Yeast. 1998, 14 (2): 161-169. 10.1002/(SICI)1097-0061(19980130)14:2<161::AID-YEA208>3.0.CO;2-Y.View ArticleGoogle Scholar
- Sleep D, Finnis C, Evans L: Enhanced protein expression through strain selection, gene disruption, improved vector design and co-expression of endogenous chaperones. Microb Cell Fact. 2006, 5 (Suppl 1): S29- 10.1186/1475-2859-5-S1-S29. S29.View ArticleGoogle Scholar
- Chinery SA, Hinchliffe E: A novel class of vector for yeast transformation. Curr Genet. 1989, 16 (1): 21-25. 10.1007/BF00411079.View ArticleGoogle Scholar
- Robinson AS, Hines V, Wittrup KD: Protein disulfide isomerase overexpression increases secretion of foreign proteins in Saccharomyces cerevisiae. Biotechnology (N Y). 1994, 12 (4): 381-384. 10.1038/nbt0494-381.View ArticleGoogle Scholar
- Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K, Giuliani M, Parrilli E, Branduardi P, Lang C, et al.: Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact. 2008, 7: 11- 10.1186/1475-2859-7-11.View ArticleGoogle Scholar
- Keenan J, Pearson D, O'Driscoll L, Gammell P, Clynes M: Evaluation of recombinant human transferrin (DeltaFerrin™) as an iron chelator in serum-free media for mammalian cell culture. Cytotechnology. 2006, 51 (1): 29-37. 10.1007/s10616-006-9011-x.View ArticleGoogle Scholar
- Sargent PJ, Farnaud S, Cammack R, Zoller HM, Evans RW: Characterisation of recombinant unglycosylated human serum transferrin purified from Saccharomyces cerevisiae. Biometals. 2006, 19 (5): 513-519. 10.1007/s10534-005-5532-6.View ArticleGoogle Scholar
- Liang Q, Richardson T: Expression and characterization of human lactoferrin in yeast Saccharomyces cerevisiae. J Agric Food Chem. 1993, 41: 1800-1807. 10.1021/jf00034a053.View ArticleGoogle Scholar
- Bewley MC, Tam BM, Grewal J, He S, Shewry S, Murphy ME, Mason AB, Woodworth RC, Baker EN, MacGillivray RT: X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32. Biochemistry. 1999, 38 (8): 2535-2541. 10.1021/bi9824543.View ArticleGoogle Scholar
- Limke T, Cunningham M, Chirkova L, Voorhamme D, Standfield S, Cavallaro D: CellPrime™ recombinant human transferrin as an animal-free alternative to animal-derived transferrin or iron supplementation in cell culture applications. BioProcess International. 6 (7): 164-165.
- Sleep D, Belfield GP, Goodey AR: The secretion of human serum albumin from the yeast Saccharomyces cerevisiae using five different leader sequences. Biotechnology (N Y). 1990, 8 (1): 42-46. 10.1038/nbt0190-42.View ArticleGoogle Scholar
- Farquhar R, Honey N, Murant SJ, Bossier P, Schultz L, Montgomery D, Ellis RW, Freedman RB, Tuite MF: Protein disulfide isomerase is essential for viability in Saccharomyces cerevisiae. Gene. 1991, 108 (1): 81-89. 10.1016/0378-1119(91)90490-3.View ArticleGoogle Scholar
- Collins SH: Production of secreted proteins in yeast. Protein production by biotechnology. Edited by: Harris TJR. 1990, 61-77. London: ElsevierView ArticleGoogle Scholar
- Makey DG, Seal US: The detection of four molecular forms of human transferrin during the iron binding process. Biochim Biophys Acta. 1976, 453 (1): 250-256.View ArticleGoogle Scholar
- Bates GW, Schlabach MR: The reaction of ferric salts with transferrin. J Biol Chem. 1973, 248 (9): 3228-3232.Google Scholar
- Rine J, Strathern JN, Hicks JB, Herskowitz I: A suppressor of mating-type locus mutations in Saccharomyces cerevisiae: evidence for and identification of cryptic mating-type loci. Genetics. 1979, 93 (4): 877-901.Google Scholar
- Payne T, Finnis C, Evans LR, Mead DJ, Avery SV, Archer DB, Sleep D: Modulation of chaperone gene expression in mutagenized Saccharomyces cerevisiae strains developed for recombinant human albumin production results in increased production of multiple heterologous proteins. Appl Environ Microbiol. 2008, 74 (24): 7759-7766. 10.1128/AEM.01178-08.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.